Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.81 |
| ▸ | EGFR | P00533 | 1/20 | 0.81 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.81 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.81 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.81 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.81 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373530 | 0.90 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29379971 | 0.90 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16637284 | 0.90 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128569 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128361 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31658053 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31658024 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128551 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128496 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128532 | 0.87 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988357-B2 | Methods for preparation of quinazoline derivatives | ARAXES PHARMA LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988357-B2 | Methods for preparation of quinazoline derivatives | ARAXES PHARMA LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
| WO-2017100546-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 | KRAS 1369/4885EGFR 4238/4885HMOX2 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.